ECTRIMS 2021 – www.brainwork.md

29th October 2021

Getting the complete clinical picture: A closer look at smouldering MS

https://www.brainwork.md/content/uploads/2021/10/MPR919-Brainwork-ECTRIMS-Illustrations-V00-05-20211012_illustration-02_inflammation-.png 6641 3734 Howard Donohue, PhD Howard Donohue, PhD https://secure.gravatar.com/avatar/7d0af6ce1f456871ef502d2e984812d6?s=96&d=mm&r=g 29th October 2021 24th January 2022

Multiple sclerosis (MS) is an inflammatory disease that is often dominated by relapsing-remitting symptoms.1 However, inflammation is not only present in acute and relapsing MS, but also in the secondary…

Howard Donohue, PhD
0
0

29th October 2021

Expanded interval dosing of natalizumab: Outcomes from the NOVA study

https://www.brainwork.md/content/uploads/2021/10/MPR919-Brainwork-ECTRIMS-Illustrations-V00-05-20211012_illustration-04_antibody.png 6641 3734 Howard Donohue, PhD Howard Donohue, PhD https://secure.gravatar.com/avatar/7d0af6ce1f456871ef502d2e984812d6?s=96&d=mm&r=g 29th October 2021 1st November 2021

Natalizumab 300 mg every 4 weeks (Q4W) is approved for the treatment of relapsing-remitting multiple sclerosis (MS). In patients previously exposed to the JC virus, natalizumab is associated with a…

Howard Donohue, PhD
0
0

29th October 2021

Aquaporin-4-positive neuromyelitis optica spectrum disorder: A favourable long-term benefit-risk profile of eculizumab treatment

https://www.brainwork.md/content/uploads/2021/10/MPR919-Brainwork-ECTRIMS-Illustrations-V00-06-20211013_illustration-05_nerve.png 6641 3734 Howard Donohue, PhD Howard Donohue, PhD https://secure.gravatar.com/avatar/7d0af6ce1f456871ef502d2e984812d6?s=96&d=mm&r=g 29th October 2021 1st November 2021

Neuromyelitis optica spectrum disorder (NMOSD) is an uncommon inflammatory disease that typically affects the optic nerves and spinal cord.1,2 At least two-thirds of cases are associated with aquaporin-4 (AQP4) antibodies…

Howard Donohue, PhD
0
0

22nd October 2021

Integrative medicine for multiple sclerosis: Outcomes from the Inspire MS program

https://www.brainwork.md/content/uploads/2021/10/MPR919-Brainwork-ECTRIMS-Illustrations-V00-06-20211019_illustration-01_Wellness.png 5692 3201 Howard Donohue, PhD Howard Donohue, PhD https://secure.gravatar.com/avatar/7d0af6ce1f456871ef502d2e984812d6?s=96&d=mm&r=g 22nd October 2021 29th October 2021

A growing body of evidence suggests that integrative medicine (IM) modalities can enhance the comprehensive care of patients with multiple sclerosis (MS). Thirty to eighty percent of patients with MS…

Howard Donohue, PhD
0
0

20th October 2021

To stay or to switch? Assessing long-term treatment outcomes and impact of treatment on patients’ quality of life

https://www.brainwork.md/content/uploads/2021/10/MPR919-Brainwork-ECTRIMS-Illustrations-V00-05-20211012_illustration-03_stay_or_switch.png 6641 3734 Howard Donohue, PhD Howard Donohue, PhD https://secure.gravatar.com/avatar/7d0af6ce1f456871ef502d2e984812d6?s=96&d=mm&r=g 20th October 2021 29th October 2021

The main concerns of patients, regarding their treatment, include disease control and safety, but they also want to make sure that their day-to-day life remains as close to normal as…

Howard Donohue, PhD
0
0